Multi-national pharmaceutical company AstraZeneca International has licensed a database created by Ann Arbor start-up Compendia Bioscience, Inc., created for cancer profiling.
Excerpt:
Officials at Compendia Bioscience Inc. of Ann Arbor said the recent deal with the $69 billion London-based drugmaker takes its product's market penetration into 10 of the top 20 pharma companies in the world.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.